Current status of the research on targeted therapy for cholangiocarcinoma
DOI:10.3969/j.issn.1001-5256.2020.12.046
- VernacularTitle:胆管癌靶向治疗的研究现状
- Author:
Haimin DENG
1
;
Huaxin DUAN
Author Information
1. Department of Oncology, The First Affiliated Hospital of Hunan Normal University & Hunan Provincial People’s Hospital, Changsha 410000, China
- Publication Type:Research Article
- Keywords:
bile duct neoplasms;
molecular targeted therapy;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(12):2856-2859
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma is a malignant tumor originating from the epithelium of bile ducts, and although it has a low incidence rate, most patients are in the end stage at the time of diagnosis since there are no prominent clinical manifestations at disease onset. Since there are problems such as insufficient treatment options, poor prognosis, and low survival rates, it is urgent to find new treatment methods to make breakthroughs in the treatment of cholangiocarcinoma. With the in-depth studies on cholangiocarcinoma gene mapping and the development of next-generation sequencing technologies, a number of potential targets have been discovered, such as FGFR and IDH1/2, making targeted therapy for cholangiocarcinoma a feasible treatment option. Targeted therapy is a treatment modality that blocks the growth of tumor cells by interfering with the specific molecules involved in tumor cell growth, with the advantages of high specificity, low toxicity, and considerable therapeutic effect. In recent years, targeted therapy has become a research hotspot in the treatment of cholangiocarcinoma. This article elaborates on the current status and challenges in targeted therapy for cholangiocarcinoma.
